Shanghai Fosun Pharmaceutical Secures Regulatory Approval for Diabetes Combination Drug

Stock News

08/03

Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (600196.SH) announced that its subsidiary, Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd., has received regulatory approval from the National Medical Products Administration for its Empagliflozin and Metformin Hydrochloride Extended-Release Tablets (III).

The approved indication is for use alongside diet and exercise to improve blood glucose control in adult patients with type 2 diabetes who are already receiving treatment with empagliflozin and metformin hydrochloride.

This new drug approval is expected to broaden the company's product portfolio and strengthen its position in the diabetes treatment market.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1111997866"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1111997866\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1111997866?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-03 16:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111997866","market":"fut","top_or_hot":-1,"title":"Shanghai Fosun Pharmaceutical Secures Regulatory Approval for Diabetes Combination Drug","media":"Stock News","content":"<p><b>Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.</b> (600196.SH) announced that its subsidiary, Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd., has received regulatory approval from the National Medical Products Administration for its Empagliflozin and Metformin Hydrochloride Extended-Release Tablets (III).<br><br>The approved indication is for use alongside diet and exercise to improve blood glucose control in adult patients with type 2 diabetes who are already receiving treatment with empagliflozin and metformin hydrochloride.<br><br>This new drug approval is expected to broaden the company's product portfolio and strengthen its position in the diabetes treatment market.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Fosun Pharmaceutical Secures Regulatory Approval for Diabetes Combination Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Fosun Pharmaceutical Secures Regulatory Approval for Diabetes Combination Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-03 16:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.</b> (600196.SH) announced that its subsidiary, Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd., has received regulatory approval from the National Medical Products Administration for its Empagliflozin and Metformin Hydrochloride Extended-Release Tablets (III).<br><br>The approved indication is for use alongside diet and exercise to improve blood glucose control in adult patients with type 2 diabetes who are already receiving treatment with empagliflozin and metformin hydrochloride.<br><br>This new drug approval is expected to broaden the company's product portfolio and strengthen its position in the diabetes treatment market.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0196","symbol_name":"行业龙头","start_time":0,"source_url":"","article_id":"1111997866","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111997866","pubTimestamp":1785746419,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (600196.SH) announced that its subsidiary, Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd., has received regulatory approval from the National...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0196":"行业龙头","02196":"复星医药","BK0175":"白马股","BK0187":"一线龙头","BK0060":"抗癌","BK0096":"民营医院","BK0012":"证金概念","BK1515":"抗疫概念","III":"信息服务","BK4134":"信息科技咨询与其它服务","BK1191":"制药","BK0028":"国家队","BK0239":"医药制造","BK0183":"MSCI概念","BK0188":"融资融券","BK1593":"医美概念股"},"translate_title":"上海复星医药糖尿病联合用药获监管部门批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"III":1,"02196":1},"content_text":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (600196.SH) announced that its subsidiary, Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd., has received regulatory approval from the National Medical Products Administration for its Empagliflozin and Metformin Hydrochloride Extended-Release Tablets (III).The approved indication is for use alongside diet and exercise to improve blood glucose control in adult patients with type 2 diabetes who are already receiving treatment with empagliflozin and metformin hydrochloride.This new drug approval is expected to broaden the company's product portfolio and strengthen its position in the diabetes treatment market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}